HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walenga, J. M. Articles by Pifarre, R. Search for Related Content PubMed PubMed Citation Articles by Walenga, J. M. Articles by Pifarre, R.

The Annals of Thoracic Surgery, Vol 51, 271-277, Copyright © 1991 by The Society of Thoracic Surgeons

ARTICLES

Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model

JM Walenga, M Bakhos, HL Messmore, J Fareed and R Pifarre
Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, Illinois.

Recombinant (r) hirudin is a potent thrombin-specific inhibitor derived from the natural hirudin of the leech (Hirudo medicinalis). We have studied the efficacy of r-hirudin compared with heparin in a canine model of cardiopulmonary bypass operations. Two administration regimens were used for r-hirudin: group 1, 1.0 mg/kg intracardiac bolus then intravenous bolus at 30 minutes (n = 10); and group 2, 1.0 mg/kg intracardiac bolus with 1.25 +/- 0.04 mg.kg-1.h-1 intravenous infusion (n = 8). Group 3 was given an intracardiac bolus of heparin, 1.66 mg/kg (n = 9). Aspiration of blood from the chest cavity revealed no significant difference between the three groups. Measurement of fibrin deposits in the pump line filter revealed higher amounts in the r- hirudin groups (p = 0.02). Decreases in platelets, fibrinogen, and hematocrit due primarily to hemodilution were the same in each group. The bleeding time assay showed less prolongation for r-hirudin than for heparin (p less than 0.001). No antagonist for r-hirudin was used; however, due to its short half-life all coagulation variables returned to baseline within 30 minutes after cardiopulmonary bypass. Because r- hirudin lacks effect on platelets, is a poor immunogen, does not require a plasma cofactor, and may not require an antagonist, it may provide an alternative anticoagulant to heparin in cardiopulmonary bypass. Additional studies are, however, needed to optimize the dose and to evaluate other clinical aspects of r-hirudin.

This article has been cited by other articles:

				F. Follis and C. A. Schmidt Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis Ann. Thorac. Surg., December 1, 2000; 70(6): 2173 - 2181. [Abstract] [Full Text] [PDF]

				J. W. Frederiksen Cardiopulmonary bypass in humans: bypassing unfractionated heparin Ann. Thorac. Surg., October 1, 2000; 70(4): 1434 - 1443. [Abstract] [Full Text] [PDF]

				E. Belougne-Malfattie, O. Aguejouf, L. Labrousse, and C. Doutremepuich A Comparison of Heparin and New Anticoagulants for Cardiopulmonary Bypass Surgery Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 118 - 125. [Abstract] [PDF]

				F.-C. Riess, C. Lower, C. Seelig, N. Bleese, J. Kormann, G. Muller-Berghaus, and B. Potzsch Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man J. Thorac. Cardiovasc. Surg., July 1, 1995; 110(1): 265 - 267. [Full Text]

				R. Pifarre State-of-the-Art Review: Optimal Anticoagulation in Cardiovascular Surgery Clinical and Applied Thrombosis/Hemostasis, June 1, 1995; 1(3): 173 - 178. [Abstract] [PDF]

				J. M. Walenga, J. Fareed, R. L. Bick, and R. Pifarre New Anticoagulants for the Cardiovascular Patient Clinical and Applied Thrombosis/Hemostasis, January 1, 1995; 1(1): 24 - 30. [Abstract] [PDF]

				A. Bernabei, A. K. Rao, S. Niewiarowski, R. W. Colman, L. Sun, and L. H. Edmunds Jr. Recombinant desulfatohirudin as a substitute for heparin during cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., August 1, 1994; 108(2): 381 - 381. [Full Text]